메뉴 건너뛰기




Volumn 15, Issue 12, 2008, Pages 1147-1153

Aminobisphosphonates as new weapons for γδ T cell-based immunotherapy of cancer

Author keywords

Bisphosphonates; Human T cells; Immunotherapy; Phosphoantigens; Tumors

Indexed keywords

ALENDRONIC ACID; AMINOBISPHOSPHONIC ACID DERIVATIVE; ANTIGEN; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; BROMOHYDRIN PYROPHOSPHATE; CLODRONIC ACID; ETIDRONIC ACID; IBANDRONIC ACID; INTERLEUKIN 2; INTERLEUKIN 21; ISOPRENOID; NERIDRONIC ACID; PAMIDRONIC ACID; PHOSPHOANTIGEN; PHOSPHOSTIM; PLACEBO; RISEDRONIC ACID; ZOLEDRONIC ACID; IMMUNOLOGICAL ADJUVANT; LYMPHOCYTE ANTIGEN RECEPTOR;

EID: 45849147320     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986708784310468     Document Type: Review
Times cited : (28)

References (81)
  • 53
    • 0036025155 scopus 로고    scopus 로고
    • Lopez, R.D. Immunol. Res. 2002, 26(1-3), 207-21.
    • (2002) Immunol. Res , vol.26 , Issue.1-3 , pp. 207-221
    • Lopez, R.D.1
  • 64
    • 0036527342 scopus 로고    scopus 로고
    • FDA approves ZOMETA for treatment of cancer-related bone complications
    • FDA approves ZOMETA for treatment of cancer-related bone complications. Expert. Rev. Anticancer. Ther. 2002, 2, 137.
    • (2002) Expert. Rev. Anticancer. Ther , vol.2 , pp. 137


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.